CMS Proposes Limited LVAD Destination Therapy Coverage Expansion
This article was originally published in The Gray Sheet
Executive Summary
Medicare coverage for left ventricular assist devices as destination therapy would gain a limited expansion under an Aug. 19 CMS proposed national coverage decision
You may also be interested in...
News In Brief
Ecolab buys O.R. Solutions
News In Brief
Ecolab buys O.R. Solutions
Thoratec Continues Push For Class IIIB Patient Inclusion In LVAD Coverage
Thoratec is continuing to advocate for left ventricular assist device destination therapy Medicare coverage expansion that includes New York Heart Association Class IIIB patients, though the firm acknowledges CMS is unlikely to alter its proposed coverage expansion limited to Class IV patients